Ola Nakken1,2, Jonas Christoffer Lindstrøm1,3, Ole-Bjørn Tysnes4,5, Trygve Holmøy1,2. 1. a Institute of Clinical Medicine , Campus Ahus, University of Oslo , Oslo , Norway. 2. b Department of Neurology , Akershus University Hospital , Lørenskog , Norway. 3. c Helse Sør-Øst Health Services Research Centre , Akershus University Hospital , Lørenskog , Norway. 4. d Department of Clinical Medicine , University of Bergen , Bergen , Norway , and. 5. e Department of Neurology , Haukeland University Hospital , Bergen , Norway.
Abstract
OBJECTIVE: In Norway, diagnoses from specialist health care visits, drug prescriptions, and causes of deaths are registered in compulsory health registers. We aimed to determine amyotrophic lateral sclerosis (ALS) prevalence from 2009 to 2015 by combining these registers. METHODS: We validated the Norwegian Patient Registry (NPR) through hospital files, and linked it with the Norwegian Cause of Death Registry and the Norwegian Prescription Database. Poisson regression models were fitted for estimating gender ratios, time trends and possible interactions. Similar models were used for mortality data subtracted from the dataset. RESULTS: Eleven percent of patients with at least one ALS-related entry in NPR did not have ALS. ALS prevalence could nevertheless be reliably estimated through ascertaining cases identified in two separate registers, or with at least two entries in NPR with first entry within four years prior to prevalence date. ALS prevalence remained stable, and was 7.6/100,000 (95% CI 6.9-8.4) at 31st December 2015. Mean male:female ratio was higher for prevalence (1.8; 95% CI 1.6-2.0) than for mortality (1.5; 95% CI 1.2-1.8) (p = 0.04). There were also significant regional differences in prevalence (p < 0.01) but not in mortality. CONCLUSIONS: Norwegian compulsory health registers provide reliable tools for ALS surveillance, and suggest gender and regional differences in survival after diagnosis.
OBJECTIVE: In Norway, diagnoses from specialist health care visits, drug prescriptions, and causes of deaths are registered in compulsory health registers. We aimed to determine amyotrophic lateral sclerosis (ALS) prevalence from 2009 to 2015 by combining these registers. METHODS: We validated the Norwegian Patient Registry (NPR) through hospital files, and linked it with the Norwegian Cause of Death Registry and the Norwegian Prescription Database. Poisson regression models were fitted for estimating gender ratios, time trends and possible interactions. Similar models were used for mortality data subtracted from the dataset. RESULTS: Eleven percent of patients with at least one ALS-related entry in NPR did not have ALS. ALS prevalence could nevertheless be reliably estimated through ascertaining cases identified in two separate registers, or with at least two entries in NPR with first entry within four years prior to prevalence date. ALS prevalence remained stable, and was 7.6/100,000 (95% CI 6.9-8.4) at 31st December 2015. Mean male:female ratio was higher for prevalence (1.8; 95% CI 1.6-2.0) than for mortality (1.5; 95% CI 1.2-1.8) (p = 0.04). There were also significant regional differences in prevalence (p < 0.01) but not in mortality. CONCLUSIONS: Norwegian compulsory health registers provide reliable tools for ALS surveillance, and suggest gender and regional differences in survival after diagnosis.
Entities:
Keywords:
Amyotrophic lateral sclerosis; epidemiology; motor neuron disease; prevalence
Authors: Petra Kotanen; Hanna-Riikka Kreivi; Aki Vainionpää; Hannu Laaksovirta; Pirkko Brander; Waltteri Siirala Journal: ERJ Open Res Date: 2020-11-10
Authors: Adriaan D de Jongh; Ruben P A van Eijk; Susan M Peters; Michael A van Es; Anja M C Horemans; Anneke J van der Kooi; Nicol C Voermans; Roel C H Vermeulen; Jan H Veldink; Leonard H van den Berg Journal: Neurology Date: 2021-01-20 Impact factor: 9.910